abstract |
The present invention relates to the identification of fusion proteins comprising polypeptide and protein variants of Fibroblast Growth Factor (FGF1) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-related disorders, including metabolic conditions. |